The vaccine showed promise. The data showed gaps.
In a country that bears the world's heaviest tuberculosis burden and has pledged to eliminate the disease by year's end, India's drug regulator has asked Bharat Biotech to do more before enrolling thousands of people in large-scale trials of MTBVAC — a vaccine candidate that has traveled further than any other of its kind. The decision is not a door closed, but a threshold raised: safety gaps, missing age-stratified analyses, and unvalidated immune response data must be resolved before the science can advance. It is a moment that holds in tension the imperative to move quickly and the older, harder obligation to move carefully.
- India's TB elimination deadline of 2026 is already within sight, yet one of its most promising vaccine candidates has been stopped at the regulatory gate before large-scale trials could begin.
- The regulator found the submission incomplete — not because the vaccine failed, but because the evidence around it had too many silences: no age-stratified results, no reconfirmed immunogenicity datasets, no genomic analysis of a serious adverse event.
- Bharat Biotech's chairman called the delay routine scientific rigor, pointing out that MTBVAC remains the only live-attenuated TB vaccine in phase III testing anywhere in the world, with trials already running in Africa.
- India's regulator has now applied strict scrutiny to two TB vaccine applications in quick succession, signaling that the stakes of the epidemic demand standards that cannot be shortcut.
- Experts warn that even if Bharat Biotech resubmits and succeeds, the broader TB vaccine pipeline is starved of funding and slowed by the disease's poorly understood immune mechanisms — problems no single approval can fix.
India's drug regulator has declined to approve Bharat Biotech's application to begin large-scale human trials of MTBVAC, a tuberculosis vaccine considered among the most advanced in the world. The Subject Expert Committee, advising the Central Drugs Standard Control Organisation, reviewed interim data from earlier-stage testing and found it incomplete — not enough to justify enrolling thousands of participants in a phase III trial.
The vaccine itself had shown genuine promise. In phase II testing, MTBVAC produced immune responses comparable to BCG, the century-old standard. But the committee identified what was missing: immunogenicity findings had not been reconfirmed with additional datasets, results had not been broken down by age group, and when a serious adverse event occurred, no genomic analysis had been done to determine whether the vaccine or wild tuberculosis exposure was responsible. The committee asked the company to resubmit with revised protocols, clearer endpoints, and a comprehensive response to each concern.
Bharat Biotech's executive chairman, Krishna Ella, described the pause as routine scientific process and confirmed the company would comply. He noted that MTBVAC is the only live-attenuated TB vaccine to have reached phase III anywhere in the world, with efficacy trials already underway in Africa.
The delay lands at a fraught moment. India accounts for more tuberculosis cases and deaths than any other country, and the government has committed to eliminating the disease by the end of 2026 — five years ahead of the United Nations target. That ambition depends on vaccines that work in adolescents and adults, populations where BCG offers little protection and where most transmission occurs.
The pattern is becoming familiar. Months earlier, the same committee rejected Serum Institute of India's application to market a separate TB vaccine, citing insufficient data. Public health experts are divided in their response: some emphasize that rigorous safety verification is non-negotiable, while others, including former WHO chief scientist Soumya Swaminathan, point to a structural problem — TB vaccine development has always moved slowly because the disease's immune mechanisms are poorly understood, trials take years, and global funding remains inadequate. The regulatory caution is defensible. But the cost of delay, measured in lives and in the distance between India's ambitions and its tools, is real.
India's drug regulator has put the brakes on Bharat Biotech's plan to move forward with large-scale human trials of MTBVAC, a tuberculosis vaccine that researchers consider among the world's most promising candidates. The Subject Expert Committee, which advises India's Central Drugs Standard Control Organisation, reviewed the company's interim data from earlier-stage testing and found the submission incomplete—too many gaps in safety documentation, too many questions left unanswered before thousands of people could be enrolled in the next phase of testing.
The vaccine itself showed promise. In phase II trials, MTBVAC generated immune responses that matched what the century-old BCG vaccine produces, the standard against which new TB vaccines are measured. The company had collected 90 days of safety data and 56 days of immunogenicity data—the measure of how well a vaccine trains the immune system to recognize and fight disease. On the surface, the numbers looked good. But the committee saw what wasn't there: the company had not reconfirmed those immunogenicity findings with additional datasets. It had not broken down the results by age group, showing separately how adolescents and adults responded. It had not validated the immune response measurements against the raw data underlying them. When a serious adverse event occurred, the committee wanted genomic analysis to determine whether it came from the vaccine itself or from wild tuberculosis exposure.
The regulatory decision amounts to a structured rejection—not a permanent one, but a clear signal that more work is required. The committee asked Bharat Biotech to resubmit immunogenicity data from specific timepoints, to revise the entire phase III protocol with clearer endpoints for measuring whether the vaccine actually prevents disease, and to provide a comprehensive plan addressing each concern. Only then would approval be reconsidered. Krishna Ella, Bharat Biotech's executive chairman, framed the delay as routine scientific rigor. He noted that MTBVAC is the only live-attenuated tuberculosis vaccine to reach phase III testing anywhere in the world, with efficacy trials already underway in Africa. He said the company would comply with the regulator's requests and hoped to begin Indian trials soon.
The timing matters. India carries the world's heaviest tuberculosis burden—more cases, more deaths, more ongoing transmission than any other country. The government has set an ambitious target: eliminate tuberculosis by the end of 2026, five years ahead of the United Nations deadline. That goal depends partly on better vaccines, ones that work not just in infants but in adolescents and adults, where most disease occurs and where BCG offers little protection. A delay in approving trials here means less Indian data, slower progress toward a vaccine tailored to India's epidemic.
This is not the first setback. Months earlier, the same regulatory committee rejected Serum Institute of India's application to market a new TB vaccine, saying the test data were insufficient and inconclusive. The pattern suggests that India's drug regulator is applying strict standards to TB vaccine candidates—a posture that experts say reflects the stakes involved. Dr. Sushila Kataria, a public health physician at Medanta hospital, noted that verifying safety data over additional months is essential; a vaccine that harms people would be worse than no vaccine at all. But Dr. Soumya Swaminathan, former chief scientist at the World Health Organization and now principal advisor to India's National Tuberculosis Elimination Programme, pointed to a deeper problem: TB vaccine development has always moved slowly because tuberculosis's immune mechanisms remain poorly understood, trials take years, and funding is scarce. She called for a significant increase in global investment to attract more companies into the field.
Bharat Biotech now faces a choice: invest the time and resources to satisfy the regulator's demands, or redirect its efforts elsewhere. The company has indicated it will comply. But the delay underscores a tension in India's health policy: the urgency of the TB elimination target and the caution required to ensure that new tools are genuinely safe and effective. The vaccine may be ready. The data may be there. But the regulator has decided that proving it requires more work.
Notable Quotes
The committee has asked us to re-present and reconfirm certain immunogenicity data and refine elements of our phase 3 trial design before approval—a constructive step.— Krishna Ella, executive chairman, Bharat Biotech
Verifying strong safety data over a few additional months is essential to ensure it does no harm.— Dr. Sushila Kataria, vice-chairman of internal medicine and public health expert, Medanta
The Hearth Conversation Another angle on the story
Why did the regulator say no when the vaccine showed immune responses comparable to BCG?
They didn't say the vaccine doesn't work. They said Bharat Biotech hadn't done the homework to prove it thoroughly enough. The company presented 56 days of immunogenicity data, but the committee wanted them to reconfirm those findings with additional datasets and break down results by age group. It's the difference between showing your work and just writing down the answer.
What's the practical impact of this delay?
India is trying to eliminate TB by the end of 2026. Every month a vaccine trial is delayed is a month fewer people can be enrolled, fewer data points collected, less evidence that a new vaccine actually prevents disease in Indian populations. The regulator is being cautious, which is defensible, but caution has a cost.
Is this regulator being unusually strict?
Not necessarily. They rejected Serum Institute's TB vaccine application a few months ago too. But TB vaccines are genuinely hard—the disease's immune mechanisms aren't fully understood, trials take years, and there's little funding. The regulator may be applying the same standards it would to any vaccine, but TB vaccine development is already moving slowly. Stricter scrutiny can feel like a luxury India doesn't have.
What does Bharat Biotech have to do now?
Resubmit immunogenicity data from specific timepoints, provide age-stratified analyses, validate immune response measurements against raw datasets, do genomic analysis of any serious adverse events, and completely revise the phase III protocol with clearer efficacy endpoints. It's not insurmountable, but it's substantial work.
Could this vaccine actually change India's TB situation?
Potentially. MTBVAC is the only live-attenuated TB vaccine to reach phase III anywhere. If it works in adolescents and adults—where BCG fails—it could be transformative. But that's a big if, and proving it requires the kind of rigorous data the regulator is demanding.